Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight dataMartin Maier, PhD nominated to Board with Annual General
… ProQR Announces AnnualMeeting of Shareholders LEIDEN, the Netherlands, April 10, … N.V. (Nasdaq:PRQR) today announced that the AnnualGeneralMeeting of Shareholders will be held on Wednesday, …
… ProQR Announces AnnualMeeting of Shareholders LEIDEN, Netherlands and CAMBRIDGE, … genetic rare diseases, today announced that the AnnualGeneralMeeting of Shareholders will be held on Tuesday, May …
… ProQR Announces AnnualMeeting of Shareholders LEIDEN, the Netherlands, April 11, … and cystic fibrosis, today announced that the AnnualGeneralMeeting of Shareholders will be held on Wednesday, …
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas
Stre
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;
Strategic convertible debt financing extends runway into 2023 if fully draw